Brief: Sirnaomics Announces Positive Interim Data From Phase Iib Clinical Trial Of Stp705 In Adults With Cutaneous Squamous Cell Carcinoma In Situ
14/12/2022 20:25
Dec 14 (Reuters) - Sirnaomics Ltd 2257.HK :
* SIRNAOMICS ANNOUNCES POSITIVE INTERIM DATA FROM PHASE IIB
CLINICAL TRIAL OF STP705 IN ADULTS WITH CUTANEOUS SQUAMOUS CELL
CARCINOMA IN SITU
* SIRNAOMICS LTD - INTERIM RESULTS SHOWED THAT MAJORITY
(78%) OF
32 PATIENTS WITH STP705 TREATMENT ACHIEVED HISTOLOGICAL
CLEARANCE
* SIRNAOMICS LTD - THERE WERE NO TREATMENT-RELATED AE'S OR
SAE'S
AND LOCAL SKIN RESPONSE SCORES WERE STABLE OR IMPROVED ACROSS
ALL TREATMENT GROUPS
Source text for Eikon: ID:nPn5rWBqXa
Further company coverage: 2257.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sirnaomics
See all newsBrief: Sirnaomics Announces RMB30 Million Capital Injection For Deemed Disposal
Brief: Sirnaomics And Unit Files Writ Of Summons Against Former Management
Brief: Sirnaomics To Issue 2.4 Million New Shares At Hk$4.69 Each Under General Mandate
Brief: Sirnaomics Says Chairman Purchases 38,000 Shares At Average Price Hk$5.93 Per Share
Brief: Sirnaomics Ltd To Issue 17.4 Million Subscription Shares